Pharmaceutical

Risk adjusted net present value: What is the current valuation of Novo Nordisk’s (Insulin icodec + Semaglutide)?

(Insulin icodec + Semaglutide) is a recombinant peptide and recombinant protein commercialized by Novo Nordisk, with a leading Phase III program in Type 2 Diabetes.

Mar 13, 2024 - 18:29
(Insulin icodec + Semaglutide) is a recombinant peptide and recombinant protein commercialized by Novo Nordisk, with a leading Phase III program in Type 2 Diabetes.
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of AstraZeneca’s ...

Next Article

Risk adjusted net present value: What is the current valuation of Novo Nordisk’s...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Emergent scores US medical countermeasure contracts worth over $250m

Emergent scores US medical countermeasure contracts wor...

Jul 4, 2024

STAT+: ‘A tug of war’: Europe braces for new legislation with far-reaching impacts on pharma and patients

STAT+: ‘A tug of war’: Europe braces for new legislatio...

Apr 25, 2023

Malaysia approves Antengene’s XPOVIO NDA for multiple myeloma

Malaysia approves Antengene’s XPOVIO NDA for multiple m...

Aug 7, 2024